Polymorphisms in the genes coding for iron binding and transporting proteins are associated with disability, severity, and early progression in multiple sclerosis

BMC Medical Genetics

Volumn 13, Issue , 2012, Pages

  Gemmati, Donato ^a   Zeri, Giulia ^a   Orioli, Elisa ^a   De Gaetano, Francesca E ^a   Salvi, Fabrizio ^b   Bartolomei, Ilaria ^b   D'Alfonso, Sandra ^c   Dall'Osso, Claudia ^d,e   Leone, Maurizio A ^f   Singh, Ajay V ^d   Asselta, Rosanna ^d   Zamboni, Paolo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b BELLARIA HOSPITAL   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e HARVARD UNIVERSITY   (United States)

^f MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FERROPORTIN; HEPCIDIN; HFE PROTEIN; TRANSFERRIN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GENE LOCUS; GENETIC CODE; GENOTYPE; HEMOCHROMATOSIS; HOMOZYGOTE; HUMAN; IRON ABSORPTION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PYROSEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL;

ADULT; ANTIMICROBIAL CATIONIC PEPTIDES; CATION TRANSPORT PROTEINS; DISEASE PROGRESSION; FEMALE; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON-BINDING PROTEINS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SEVERITY OF ILLNESS INDEX; TRANSFERRIN;

EID: 84868621323     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-13-70     Document Type: Article

References (59)

1. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med 2006, 354:942-955. 10.1056/NEJMra052130, 16510748.
2. LeVine SM. Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res 1997, 760:298-303. 10.1016/S0006-8993(97)00470-8, 9237552.
3. Adams CW. Perivascular iron deposition and other vascular damage in multiple sclerosis. J Neurol Neurosurg Psychiatry 1988, 51:260-265. 10.1136/jnnp.51.2.260, 1031540, 3346691.
4. Adams CW, Poston RN, Buk SJ. Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis. J Neurol Sci 1989, 92:291-306. 10.1016/0022-510X(89)90144-5, 2809622.
5. Stankiewicz J, Panter SS, Neema M, Arora A, Batt CE, Bakshi R. Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics 2007, 4:371-386. 10.1016/j.nurt.2007.05.006, 1963417, 17599703.
6. Sullivan JL. Is stored iron safe?. J Lab Clin Med 2004, 144:280-284. 10.1016/j.lab.2004.10.006, 15614249.
7. Emerit J, Beaumont C, Trivi F. Iron metabolism, free radicals, and oxidative injury. Biomed Pharmacother 2001, 55:333-339. 10.1016/S0753-3322(01)00068-3, 11478586.
8. Rouault TA, Cooperman S. Brain iron metabolism. Semin Pediatr Neurol 2006, 13:142-148. 10.1016/j.spen.2006.08.002, 17101452.
9. Stankiewicz JM, Brass SD. Role of iron in neurotoxicity: a cause for concern in the elderly?. Curr Opin Clin Nutr Metab Care 2009, 12:22-29. 10.1097/MCO.0b013e32831ba07c, 19057183.
10. Li X, Jankovic J, Le W. Iron chelation and neuroprotection in neurodegenerative diseases. J Neural Transm 2011, 118:473-477. 10.1007/s00702-010-0518-0, 21161300.
11. LeVine SM, Chakrabarty A. The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis. Ann N Y Acad Sci 2004, 1012:252-266. 10.1196/annals.1306.021, 15105271.
12. Zamboni P. The big idea: iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis. J R Soc Med 2006, 99:589-593. 10.1258/jrsm.99.11.589, 1633548, 17082306.
13. Simka M, Rybak Z. Hypothetical molecular mechanisms by which local iron overload facilitates the development of venous leg ulcers and multiple sclerosis lesions. Med Hypotheses 2008, 71:293-297. 10.1016/j.mehy.2008.02.009, 18400414.
14. Zamboni P, Izzo M, Tognazzo S, Carandina S, De Palma M, Catozzi L, Caggiati A, Scapoli G, Gemmati D. The overlapping of local iron overload and HFE mutation in venous leg ulcer pathogenesis. Free Radic Biol Med 2006, 40:1869-1873. 10.1016/j.freeradbiomed.2006.01.026, 16678024.
15. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A. A novel MHC class I like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996, 13:399-408. 10.1038/ng0896-399, 8696333.
16. Gemmati D, Federici F, Catozzi L, Gianesini S, Tacconi G, Scapoli GL, Zamboni P. DNA-array of gene variants in venous leg ulcers: detection of prognostic indicators. J Vasc Surg 2009, 50:1444-1451. 10.1016/j.jvs.2009.07.103, 19958990.
17. Rubio JP, Bahlo M, Tubridy N, Stankovich J, Burfoot R, Butzkueven H. Extended haplotype analysis in the HLA complex reveals an increased frequency of the HFE-C282Y mutation in individuals with multiple sclerosis. Hum Genet 2004, 114:573-580. 10.1007/s00439-004-1095-9, 15014978.
18. Ristić S, Lovrecić L, Brajenović-Milić B, Starcević-Cizmarević N, Jazbec SS, Sepcić J, Kapović M. Mutations in the hemochromatosis gene (HFE) and multiple sclerosis. Neurosci Lett 2005, 383:301-304. 10.1016/j.neulet.2005.04.045, 15955425.
19. Ramagopalan SV, Cukjati M, Cernilec M, DeLuca GC, Dyment DA, Degenhardt A. Mutations in the hemochromatosis gene and the clinical outcome of multiple sclerosis. J Neuroimmunol 2008, 203:104-107. 10.1016/j.jneuroim.2008.06.036, 18675463.
20. Bettencourt A, Silva AM, Santos E, Gomes S, Mendonça D, Costa PP. HFE gene polymorphisms and severity in Portuguese patients with multiple sclerosis. Eur J Neurol 2011, 18:663-666. 10.1111/j.1468-1331.2010.03109.x, 20586792.
21. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000, 275:19906-19912. 10.1074/jbc.M000713200, 10747949.
22. Altès A, Bach V, Ruiz A, Esteve A, Remacha AF, Sardà MP. Does the SLC40A1 gene modify HFE-related haemochromatosis phenotypes?. Ann Hematol 2009, 88:341-345. 10.1007/s00277-008-0590-9, 18820912.
23. Leong WI, Lönnerdal B. Hepcidin, the recently identified peptide that appears to regulate iron absorption. J Nutr 2004, 134:1-4.
24. Andreani M, Radio FC, Testi M, De Bernardo C, Troiano M, Majore S. Association of hepcidin promoter c.-582 A>G variant and iron overload in thalassemia major. Haematologica 2009, 94:1293-1296. 10.3324/haematol.2009.006270, 2738723, 19734422.
25. Bruno F, Bonalumi S, Camaschella C, Ferrari M, Cremonesi L. The -582A>G variant of the HAMP promoter is not associated with high serum ferritin levels in normal subjects. Haematologica 2010, 95:849-850. 10.3324/haematol.2009.018986, 2864396, 20007145.
26. Parajes S, González-Quintela A, Campos J, Quinteiro C, Domínguez F, Loidi L. Genetic study of the hepcidin gene (HAMP) promoter and functional analysis of the c.-582A > G variant. BMC Genet 2010, 11:110. 3004809, 21143959.
27. Aisen P. Transferrin, the transferrin receptor, and the uptake of iron by cells. Met Ions Biol Syst 1998, 35:585-631.
28. Lee PL, Ho NJ, O, Beutler E. The effect of transferrin polymorphisms on iron metabolism. Blood Cells Mol Dis 1999, 25:374-379. 10.1006/bcmd.1999.0267, 10660486.
29. Wong CT, Saha N. Effects of transferrin genetic phenotypes on total iron-binding capacity. Acta Haematol 1986, 75:215-218. 10.1159/000206128, 3096053.
30. Zambenedetti P, De Bellis G, Biunno I, Musicco M, Zatta P. Transferrin C2 variant does confer a risk for Alzheimer's disease in caucasians. J Alzheimers Dis 2003, 5:423-427.
31. Zhang P, Yang Z, Zhang C, Lu Z, Shi X, Zheng W. Association study between late-onset Alzheimer's disease and the transferrin gene polymorphisms in Chinese. Neurosci Lett 2003, 349:209-211. 10.1016/S0304-3940(03)00837-1, 12951205.
32. Kauwe JS. Alzheimer's Disease Neuroimaging Initiative: Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2010, 153B:955-959. 2877151, 20029940.
33. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005, 58:840-846. 10.1002/ana.20703, 16283615.
34. Lublin FD. Clinical features and diagnosis of multiple sclerosis. Neurol Clin 2005, 23:1-15. 10.1016/j.ncl.2004.09.003, 15661085.
35. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sørensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sá M, Salemi G, Savettieri G, Hillert J, Compston DA. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005, 64:1144-1151. 10.1212/01.WNL.0000156155.19270.F8, 15824338.
36. Kotze MJ, de Villiers JN, Warnich L, Schmidt S, Carr J, Mansvelt E. Lack of clinical manifestation of hereditary haemochromatosis in South African patients with multiple sclerosis. Metab Brain Dis 2006, 21:109-120.
37. Ristori G, Brescianini S, Pino A, Visconti A, Vittori D, Coarelli G. Serum elements and oxidative status in clinically isolated syndromes: imbalance and predictivity. Neurology 2011, 76:549-555. 10.1212/WNL.0b013e31820af7de, 21300970.
38. Zivadinov R, Schirda C, Dwyer MG, Haacke ME, Weinstock-Guttman B, Menegatti E, Heininen-Brown M, Magnano C, Malagoni AM, Wack DS, Hojnacki D, Kennedy C, Carl E, Bergsland N, Hussein S, Poloni G, Bartolomei I, Salvi F, Zamboni P. Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: a pilot case-control study. Int Angiol 2010, 29:158-175.
39. Neema M, Arora A, Healy BC, Guss ZD, Brass SD, Duan Y. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging 2009, 19:3-8. 10.1111/j.1552-6569.2008.00296.x, 2762230, 19192042.
40. Brass SD, Benedict RH, Weinstock-Guttman B, Munschauer F, Bakshi R. Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. Mult Scler 2006, 12:437-444. 10.1191/135248506ms1301oa, 16900757.
41. Tjoa CW, Benedict RH, Weinstock-Guttman B, Fabiano AJ, Bakshi R. MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis. J Neurol Sci 2005, 234:17-24. 10.1016/j.jns.2005.02.009, 15993137.
42. Rouault TA, Zhang DL, Jeong SY. Brain iron homeostasis, the choroid plexus, and localization of iron transport proteins. Metab Brain Dis 2009, 24:673-684. 10.1007/s11011-009-9169-y, 2788140, 19851851.
43. Pantopoulos K. Iron metabolism and the IRE/IRP regulator system: an update. Ann NY Acad Sci 2004, 1012:1-13. 10.1196/annals.1306.001, 15105251.
44. Ke Y, Qian ZM. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol 2003, 2:246-253. 10.1016/S1474-4422(03)00353-3, 12849213.
45. Zamboni P, Menegatti E, Weinstock-Guttman B, Dwyer MG, Schirda CV, Malagoni AM, Hojnacki D, Kennedy C, Carl E, Bergsland N, Magnano C, Bartolomei I, Salvi F, Zivadinov R. Hypoperfusion of brain parenchyma is associated with the severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a cross-sectional preliminary report. BMC Med 2011, 9:22. 10.1186/1741-7015-9-22, 3059278, 21385345.
46. Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Tacconi G. Dall'Ara S, Bartolomei I, Salvi F: Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009, 80:392-399. 2647682, 19060024.
47. Ferlini A, Bovolenta M, Neri M, Gualandi F, Balboni A, Yuryev A, Salvi F, Gemmati D, Liboni A, Zamboni P. Custom CGH array profiling of copy number variations (CNVs) on chromosome 6p21.32 (HLA locus) in patients with venous malformations associated with multiple sclerosis. BMC Med Genet 2010, 11:64. 2880319, 20426824.
48. van Rensburg SJ, van Toorn R. The controversy of CCSVI and iron in multiple sclerosis: is ferritin the key?. Neurology 2010, 75:1581-1582. 10.1212/WNL.0b013e3181fb44f0, 20881276.
49. Ghezzi A, Comi G, Federico A. Chronic cerebro-spinal venous insufficiency (CCSVI) and multiple sclerosis. Neurol Sci 2011, 32:17-21. 10.1007/s10072-010-0458-3, 21161309.
50. D'haeseleer M, Cambron M, Vanopdenbosch L, De Keyser J. Vascular aspects of multiple sclerosis. Lancet Neurol 2011, 10:657-666. 10.1016/S1474-4422(11)70105-3, 21683931.
51. Williams R, Buchheit CL, Berman NE, Levine SM. Pathogenic implications of iron accumulation in multiple sclerosis. J Neurochem 2012, 120:7-25. 10.1111/j.1471-4159.2011.07536.x, 22004421.
52. Jacolot S, Yang Y, Paitry P, Férec C, Mura C. Iron metabolism in macrophages from HFE hemochromatosis patients. Mol Genet Metab 2010, 101:258-267. 10.1016/j.ymgme.2010.07.010, 20675164.
53. Mayr R, Janecke AR, Schranz M, Griffiths WJ, Vogel W, Pietrangelo A. Ferroportin disease: a systematic meta-analysis of clinical and molecular findings. J Hepatol 2010, 53:941-949. 10.1016/j.jhep.2010.05.016, 2956830, 20691492.
54. Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 2000, 48:211-219. 10.1002/1531-8249(200008)48:2<211::AID-ANA11>3.0.CO;2-R, 10939572.
55. Todorich B, Pasquini JM, Garcia CI, Paez PM, Connor JR. Oligodendrocytes and myelination: the role of iron. Glia 2009, 57:467-478. 10.1002/glia.20784, 18837051.
56. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004, 55:458-468. 10.1002/ana.20016, 15048884.
57. Bartzokis G, Lu PH, Tishler TA, Peters DG, Kosenko A, Barrall KA, Finn JP, Villablanca P, Laub G, Altshuler LL, Geschwind DH, Mintz J, Neely E, Connor JR. Prevalent iron metabolism gene variants associated with increased brain ferritin iron in healthy older men. J Alzheimers Dis 2010, 20:333-341. 3119253, 20164577.
58. Bartzokis G, Lu PH, Tingus K, Peters DG, Amar CP, Tishler TA, Finn JP, Villablanca P, Altshuler LL, Mintz J, Neely E, Connor JR. Gender and iron genes may modify associations between brain iron and memory in healthy aging. Neuropsychopharmacology 2011, 36:1375-1384. 10.1038/npp.2011.22, 3096807, 21389980.
59. van Rensburg SJ, Kotze MJ, van Toorn R. The conundrum of iron in multiple sclerosis - time for an individualised approach. Metab Brain Dis 2012, 27:239-253. 10.1007/s11011-012-9290-1, 3402663, 22422107.